Clinical Trial Update: Phase I Study of AMA1-C1/Alhydrogel® (Registered Trademark) + CPG 7909 Malaria Vaccine [Phase 1]

View source ↗

Summary

Phase I study evaluating AMA1-C1/Alhydrogel with CpG 7909 as a malaria vaccine completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria

Drugs mentioned

• AMA1-C1/Alhydrogel (AMA1-C1/Alhydrogel)
• CPG 7909 (CpG 7909)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Malaria | Phase 1 | Status: COMPLETED